ALMS compared with PBLS: revenue, margins and what each company keeps, and the suppliers and customers both name

ALMSAlumis Inc.

Mkt capRevenueRevenue

PBLSParabilis Medicines, Inc.

Mkt capRevenueRevenue

Compare

ALMSAlumis Inc.

PBLSParabilis Medicines, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALMS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.3%▲+3.69%×0.15

May 15 '26±16.1%▼−7.15%×0.45

Q1 FY26±20.4%▼−1.26%×0.06

Jan 9 '26±10.1%▲+7.59%×0.75

PBLS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.65%—

= impliedALMS realized, solidPBLS realized, hatchedOne scale, both sides: full bar = 26%× = |realized| ÷ impliedSource: market data

ALMSAlumis Inc.

6.48▲+1.59%· post 6.48· delayed

Mkt cap$825.8MRevenue$2MQ2 FY26Revenue$24MFY25

PBLSParabilis Medicines, Inc.

27.29▲+0.15%· post 29.29· delayed

After hoursNov 3 '26delayed

Mkt cap$787.8MRevenue$148,000Q2 FY26Revenue—

Compare

After hoursNov 3 '26delayed

ALMSAlumis Inc.

PBLSParabilis Medicines, Inc.

6.48▲+1.59%post 6.48delayed

Price

27.29▲+0.15%post 29.29delayed

$825.8M

Mkt cap

$787.8M

Q2 FY26$2M

Revenue

$148,000Q2 FY26

FY25$24M

Revenue

—

ALMS6.48▲+1.59%vsPBLS27.29▲+0.15%After hoursNov 3 '26delayed